IRIS
TINARI, Nicola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.525
EU - Europa 5.053
AS - Asia 4.081
SA - Sud America 693
AF - Africa 57
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 9
AN - Antartide 1
Totale 16.429
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.399
SG - Singapore 1.838
CN - Cina 1.234
IT - Italia 1.043
IE - Irlanda 794
UA - Ucraina 624
BR - Brasile 589
SE - Svezia 562
GB - Regno Unito 467
DE - Germania 449
FR - Francia 445
TR - Turchia 380
VN - Vietnam 221
FI - Finlandia 203
IN - India 191
RU - Federazione Russa 121
CA - Canada 70
BE - Belgio 61
AT - Austria 54
PL - Polonia 54
NL - Olanda 53
HK - Hong Kong 44
MX - Messico 43
CZ - Repubblica Ceca 41
AR - Argentina 35
JP - Giappone 34
BD - Bangladesh 28
ZA - Sudafrica 23
IQ - Iraq 21
LT - Lituania 21
ES - Italia 19
KR - Corea 14
CO - Colombia 13
EC - Ecuador 13
ID - Indonesia 12
EG - Egitto 11
UY - Uruguay 10
AU - Australia 9
EU - Europa 9
AE - Emirati Arabi Uniti 8
MA - Marocco 8
PE - Perù 8
UZ - Uzbekistan 8
VE - Venezuela 8
IL - Israele 7
IR - Iran 7
PY - Paraguay 7
CL - Cile 6
GR - Grecia 6
PK - Pakistan 6
PT - Portogallo 6
CH - Svizzera 5
JO - Giordania 5
RO - Romania 5
BG - Bulgaria 4
DZ - Algeria 4
HN - Honduras 4
NP - Nepal 4
TW - Taiwan 4
AL - Albania 3
BO - Bolivia 3
JM - Giamaica 3
SN - Senegal 3
AZ - Azerbaigian 2
DO - Repubblica Dominicana 2
GT - Guatemala 2
KW - Kuwait 2
KZ - Kazakistan 2
LB - Libano 2
LU - Lussemburgo 2
MD - Moldavia 2
MT - Malta 2
SA - Arabia Saudita 2
TT - Trinidad e Tobago 2
AF - Afghanistan, Repubblica islamica di 1
AO - Angola 1
AQ - Antartide 1
BA - Bosnia-Erzegovina 1
BW - Botswana 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
EE - Estonia 1
ET - Etiopia 1
GY - Guiana 1
HR - Croazia 1
KE - Kenya 1
KG - Kirghizistan 1
LV - Lettonia 1
MK - Macedonia 1
MY - Malesia 1
NG - Nigeria 1
QA - Qatar 1
RS - Serbia 1
SC - Seychelles 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 16.429
Salva come PNG Salva come JPEG
Città #
Singapore 1.371
Chandler 959
Dublin 780
Jacksonville 740
Dallas 408
Ashburn 376
Beijing 349
Princeton 319
Southend 294
Nanjing 220
Los Angeles 216
Izmir 212
The Dalles 193
Munich 188
Ann Arbor 178
Pescara 175
Santa Clara 174
Chieti 158
Wilmington 144
New York 139
Dearborn 134
Altamura 121
Boardman 119
Cambridge 109
Tongling 91
Buffalo 84
Nanchang 71
Helsinki 66
São Paulo 60
Brussels 59
Ho Chi Minh City 59
Woodbridge 58
Redondo Beach 54
Dong Ket 50
Vienna 44
Hong Kong 40
Council Bluffs 38
Rome 38
Nuremberg 37
Hanoi 34
Shenyang 34
Warsaw 34
Brooklyn 33
Hebei 33
Brno 32
Ancona 31
Chicago 31
Tokyo 31
Atlanta 30
Houston 29
Kunming 29
Norwalk 29
Amsterdam 28
Milan 28
Tianjin 28
Denver 27
Montreal 27
Jiaxing 26
Turku 26
Hefei 25
Boston 24
Falls Church 24
Orem 23
Seattle 22
Washington 22
Changsha 21
London 21
Stockholm 21
Frankfurt am Main 19
Johannesburg 19
Ascoli Piceno 17
Chennai 17
Montesilvano 17
Poplar 16
Toronto 16
Hangzhou 15
Belo Horizonte 14
Hyderabad 14
Rio de Janeiro 14
Seoul 14
Campinas 13
Düsseldorf 13
Grevenbroich 13
Kraków 13
Lanzhou 13
Manchester 13
San Mateo 13
Brasília 12
Lappeenranta 12
Moscow 12
Phoenix 12
Changchun 11
Kocaeli 11
Pune 11
San Francisco 11
Giaveno 10
Guangzhou 10
Mexico City 10
Mumbai 10
Querétaro 10
Totale 10.153
Salva come PNG Salva come JPEG
Nome #
Developing a Decision-making Model Based on an Interdisciplinary Oncological Care Group for the Management of Colorectal Cancer 251
A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer. 176
90K (Mac-2 BP) and galectins in tumor progression and metastasis. 158
A comparative study of the antiinflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds 149
Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation 148
Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey 147
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. 144
Allergooncology: an expanding research area 143
The 90K tumor associated antigen and clinical progression in human immunodeficiency virus infection 141
Impact of BMI on clinical outcome in advanced cancer patients treated with anti‑PD‑1 Immune checkpoint inhibitors: a preliminary analysis 137
Gli analoghi sintetici delle glicoamine come potenziali nuovi farmaci nella prevenzione delle metastasi 135
The 90K protein increases major histocompatibility complex class I expression and is regulated by hormones, gamma-interferon, and double-strand polynucleotides. 134
New Targets for Therapy in Pancreatic Cancer 134
Prognostic relevance of LGALS3BP in human colorectal carcinoma 133
Exosomes as pleiotropic players in pancreatic cancer 131
Purification and characterization of a 90 kDa protein releasedfrom human tumors and tumor cell lines 130
Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells 129
CAR-T-Derived Extracellular Vesicles: A Promising Development of CAR-T Anti-Tumor Therapy 127
ERBB3 BINDING ANTIBODY 127
Occupational allergy: is there a role for nanoparticles? 127
Elevated serum levels of 90K/MAC-2BP predict unresponsiveness to alfa-interferon therapy in chronic HCV hepatitis patients 126
Glicomimetici quali potenziali nuovi farmaci per la prevenzione delle metastasi. 126
A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression 126
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable 124
90k is a serum marker of poor-prognosis in non-hodgkins-lymphoma patients. 123
90K (Mac-2 BP) predicts CD4 decline in human immunodeficiency virus-infected patients with CD4 counts above 200 x 10^6 cells/L 122
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 122
An Epigenetic Approach to Pancreatic Cancer Treatment: the Prospective Role of Histone Deacetylase Inhibitors 120
High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies 120
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials 120
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 120
A novel serum test using interferon for early detection of tumor reccurrence in cancer patients after radical surgery. 119
A PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY WITH CISTAPLIN, EPIRUBICIN AND VP – 16 FOR STAGE III UNRESECTABLE NON-SMALL CELL LUNG CANCER 119
Blood Circulating CD133+ Extracellular Vesicles Predict Clinical Outcomes in Patients with Metastatic Colorectal Cancer 118
Upstream stimulatory factor regulates constitutive expression and hormonal suppression of the 90K (Mac-2BP) protein. 118
A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men. 118
The Benzimidazole-Based Anthelmintic Parbendazole: A Repurposed Drug Candidate That Synergizes with Gemcitabine in Pancreatic Cancer 118
High Blood Concentration of Leukocyte-Derived Extracellular Vesicles Is Predictive of Favorable Clinical Outcomes in Patients with Pancreatic Cancer: Results from a Multicenter Prospective Study 116
Elevated serum levels of a 90,000 daltons tumor-associated antigen in cancer and in infection by human immunodeficiency virus (HIV). 116
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 115
Trop-2, Na+/K+ ATPase, CD9, PKCα, cofilin assemble a membrane signaling super-complex that drives colorectal cancer growth and invasion 115
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. 114
CD19.CAR-T cell-derived extracellular vesicles express CAR and kill leukemic cells, contributing to antineoplastic therapy 112
Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. 112
Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody. 112
Novel inhibitors of pvhl-elongin c binding 111
Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. 110
DNA ploidy and S-phase fraction in pulmonary carcinoids. 110
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study 109
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 109
An FPSE-HPLC-PDA method for the determination of anticancer drugs in human whole blood, plasma, and urine 109
TGF-β-1 increases 90K tumor associated antigen gene expression by increasing upstream regulatory factor binding to the minimal promoter. 107
Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage? Reply to Kadri Altundag 107
Principali effetti collaterali delle terapie mediche 107
BIOLOGICAL INDICATORS OF PROGNOSIS IN HUMAN CANCER: AN EMERGING ROLE FOR LECTIN GALACTOSIDE-BINDING SOLUBLE 3-BINDING PROTEIN (LGALS3BP) 107
A perspective analysis: microRNAs, glucose metabolism, and drug resistance in colon cancer stem cells 107
Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival 106
Chronomodulated infusion of cisplatin, 5-fluorouracil and folinic acid: lack of activity in advanced colorectal cancer. 106
A Flow cytometric study of early gastric cancer 106
Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study 106
Prognostic value of 90K protein in HIV infection 105
A Stochastic Model for the HIV/AIDS Dynamic Evolution 105
Inhibition of tumor growth and angiogenesis by SP-2, an anti-LGALS3BP antibody 105
Prognostic value of a novel circulating serum 90K antigen in breast cancer 103
Role of 90K protein in asthma and TH2-type cytokine expression. 103
Lack of prognostic value of immunohistochemical determination of epidermal growth-factor receptors in human prostate-cancer. 103
Prognostic value of a novel circulating serum 90K antigen in HIV-infected haemophilia patients. 103
Identification of Subgroups of Early Breast Cancer Patients at High Risk of Nonadherence to Adjuvant Hormone Therapy: Results of an Italian Survey 103
PLC-gamma-1 phosphorylation status is prognostic of metastatic risk in patients with early-stage Luminal-A and -B breast cancer subtypes 103
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study 103
Corrigendum to "Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation" 103
Tumor-derived microvesicles: The metastasomes. 102
Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer 100
Unknown primary tumors 100
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 100
Optimizing the Choice for Adjuvant Chemotherapy in Gastric Cancer 99
Concentrations of Galectin-3 in the Sera of Normal Controls and Cancer Patients 99
Expression of the 90K tumor-associated protein in benign and malignant melanocytic lesions. 98
Persistence and adherence to androgen deprivation therapy in men with prostate cancer: an administrative database study 98
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study 98
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 98
Long-term outcome of breast cancer patients with pathologic N3a lymph node stage 97
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 97
Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study. 95
Pancreatic juice 90K and serum CA 19-9 combined determination can discriminate between pancreatic cancer and chronic pancreatitis. 94
Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A “hypothesis-generator” preliminary report 94
Tgf-β1 transcriptionally promotes 90K expression: possible implications for cancer progression 94
Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. 93
Dynamic test with recombinant interferon-alpha-2b: effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease. 93
HCV genotype and serum 90K levels: host and virus related factors predict response to a-ifn therapy 92
Preoperative dose-dense sequential chemotherapy of epirubicin/cyclophosphamide followed by docetaxel/capecitabine in patients with breast cancer 91
DNA and S-phase fraction analysis by flow cytometry in prostate cancer. Clinicopathologic implications. 91
Combinations of biological response modifiers: rationale and clinical responses. 91
A stochastic model for evaluating the HIV anti-retroviral treatment patient cost: a case study 91
The 2EF Antibody Targets a Unique N-Terminal Epitope of Trop-2 and Enhances the In Vivo Activity of the Cancer-Selective 2G10 Antibody 90
Immunological effects of alternative weekly interferon–alpha–2b and low dose interleukin–2 in patients with cancer 90
EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo. 90
Effect of targeted agents on the endocrine response of breast cancer in the neoadjuvant setting: A systematic review 90
LGALS3BP, A TUMOR-ASSOCIATED ANTIGEN, UPREGULATES VEGF IN HUMAN BREAST CANCER: POSSIBLE IMPLICATIONS IN ANGIOGENESIS 90
An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling. 90
Totale 11.373
Salva come PNG Salva come JPEG
Categoria #
all - tutte 69.382
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 69.382
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021612 0 0 0 0 0 188 43 30 69 125 66 91
2021/2022891 35 22 15 174 78 37 35 69 59 22 94 251
2022/20232.683 216 341 202 307 267 483 147 236 300 22 103 59
2023/20241.415 121 46 79 63 85 457 236 54 41 40 15 178
2024/20253.722 178 606 501 105 87 184 344 237 357 216 392 515
2025/20263.392 599 320 802 846 702 123 0 0 0 0 0 0
Totale 17.123